sk&f 82958 has been researched along with Atherosclerotic Parkinsonism in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Talipexole was more potent than pramipexole (10 vs." | 1.30 | Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys. ( Domino, EF; Kohno, Y; Ni, L; Sasa, M; Zhang, H, 1997) |
| "Trihexyphenidyl was then studied in combination with the selective dopamine receptor D1 agonist SKF-82958 [(+/-)-6-chloro-7-8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro- 1H-benzazepine hydrobromide] and the selective D2 agonist N-0923 [(-)2-(N-propyl-N-2-thienylethyl)amino-5-hydroxytetralin HCl] on rotational behavior in five 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned hemiparkinsonian monkeys." | 1.30 | Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys. ( Domino, EF; Ni, L, 1998) |
| " In contrast, chronic administration of the D1-like receptor agonist CY 208243 to 6-OHDA-lesioned rats dramatically enhanced deltaFosB-like immunoreactivity in striatal neurons projecting to the substantia nigra." | 1.29 | Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. ( Bedard, PJ; Blanchet, P; Chen, JS; Doucet, JP; Grondin, R; Hope, BT; Iadarola, MJ; Jasmin, BJ; Nakabeppu, Y; Nestler, EJ; Robertson, GS; St-Jean, M; Wigle, N, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (75.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Samadi, P | 1 |
| Grégoire, L | 1 |
| Bédard, PJ | 5 |
| Bibbiani, F | 1 |
| Oh, JD | 1 |
| Kielaite, A | 1 |
| Collins, MA | 1 |
| Smith, C | 1 |
| Chase, TN | 1 |
| Nomoto, M | 1 |
| Fukuda, T | 1 |
| Doucet, JP | 1 |
| Nakabeppu, Y | 1 |
| Hope, BT | 1 |
| Nestler, EJ | 1 |
| Jasmin, BJ | 1 |
| Chen, JS | 1 |
| Iadarola, MJ | 1 |
| St-Jean, M | 1 |
| Wigle, N | 1 |
| Blanchet, P | 1 |
| Grondin, R | 4 |
| Robertson, GS | 1 |
| Blanchet, PJ | 3 |
| Goulet, M | 2 |
| Di Paolo, T | 2 |
| Domino, EF | 3 |
| Ni, L | 2 |
| Zhang, H | 1 |
| Kohno, Y | 1 |
| Sasa, M | 1 |
| Kuno, S | 1 |
| Maneuf, YP | 1 |
| Crossman, AR | 1 |
| Brotchie, JM | 2 |
| Andringa, G | 1 |
| Lubbers, L | 1 |
| Drukarch, B | 1 |
| Stoof, JC | 1 |
| Cools, AR | 1 |
| Calon, F | 1 |
| Morissette, M | 1 |
| Fox, SH | 1 |
| Rupniak, NM | 1 |
| Boyce, S | 1 |
| Steventon, M | 1 |
| Iversen, SD | 1 |
| Silverman, PB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK.[NCT00632762] | Phase 4 | 80 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 other studies available for sk&f 82958 and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Dopa | 2003 |
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Benzodiazepines; Disease | 2005 |
The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzazepines; Callithri | 1993 |
Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
Topics: Animals; Bacterial Proteins; Base Sequence; Benzazepines; Blotting, Western; Cabergoline; Corpus Str | 1996 |
Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Brain; Dopamine Agents; Dopamin | 1996 |
Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Catecholamines; Dopamine Agonis | 1996 |
Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Azepines; Basal Ganglia Diseases; Behavior, Animal; Benzazepines; Ben | 1997 |
Selective full dopamine D1-like (SKF-82958) and D2-like (N-0923) agonist combination in the MPTP monkey model of hemiparkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Disease Models, Animal; Dopamin | 1997 |
Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Benzazepin | 1997 |
The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Benzazepines; Benzoxazines; Dopamine Agonists; gamma-Aminobutyric Acid; Loco | 1997 |
Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dopamine Agonists; Dose-Response Relationship, Drug; Dr | 1998 |
The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958.
Topics: Animals; Antiparkinson Agents; Arm; Behavior, Animal; Benzazepines; Dopamine Agents; Dopamine Agonis | 1999 |
125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Basal | 2000 |
5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Disease Models, Animal; Dopamine Agon | 2000 |
Weak antiparkinsonian activity of the D1 agonist C-APB (SKF 82958) and lack of synergism with a D2 agonist in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzazepines; Dopamine | 1992 |
Sensitization, response fluctuation and long-term effect of SKF-82958 and bromocriptine in the hemi-parkinsonian rat.
Topics: Animals; Benzazepines; Bromocriptine; Dopamine Agents; Dose-Response Relationship, Drug; Female; Mot | 1992 |